Hutchison, James C.; Lutz, Bruce; Pezzi, Susan
June 1960
Angiology;Jun1960 Part 1, Vol. 11 Issue 3, p193
Academic Journal
Sixty-two hypertensive patients have been treated with a new oral antihypertensive-saluretic preparation designated as Rautrax. The blood pressure response is reported for all of the patients after 1 month, for 53 after 3 months and for 37 after 6 months of therapy. Dosage was 1 tablet of Rautrax twice daily, each tablet containing 50 mg of whole root Rauwolfia serpentina, 400 mg of a new oral saluretic agent, flumethiazide, and 400 mg of potassium chloride. Normal blood pressure readings were recorded for 30 of the 62 patients after 1 month, for 29 of the 53 after 3 months, and for 18 of the 37 patients after treatment for 6 months. Significant reductions in the blood pressure levels over pretreatment values were observed in 69 per cent, 83 per cent and 89 per cent of patients after 1, 3 or 6 months of therapy, respectively. Associated symptoms such as headache, dizziness and blurring of vision were completely relieved or greatly improved in the majority of the patients. Medication was withdrawn in two patients who developed purpura, lethargy and severe diarrhea. Other side effects included transient nasal stuffiness, itchiness, increased bowel motility, occasional weakness, epigastric discomfort and a feeling of �shockiness� in two diabetic patients, but these were never sufficiently severe to require discontinuance of the drug. Patients on digitalis therapy who received Rautrax gave no signs of digitalis intoxication. There were no signs of potassium loss in any patient, though none were anticipated because Rautrax contains added potassium to combat excessive loss. After periods of administration lasting for 6 months, there was no sign of tolerance to the antihypertensive action of Rautrax. Potentiation of the antihypertensive effect of rauwolfia by the concomitant administration of a diuretic-saluretic agent has been confirmed. On the basis of the findings in this study, the clinical impression was gained that Rautrax represents a valuable addition to the resources available to the physician for the medical management of hypertensive vascular disease. The combination of hypotensive-saluretic action in a single preparation provides a convenient dosage form in the treatment of the ambulatory patient.


Related Articles

  • Palpable effects of blood pressure tablets not all bad, say patients.  // Nursing Standard;4/26/2006, Vol. 20 Issue 33, p16 

    The article cites a study which explored patients' acceptance of the palpable side effects of antihypertensive drugs. Overall, some of the side effects were welcome, such as reduced blood pressure and increased calm. While some patients stopped taking the pills due to poor palpable effects, most...

  • Moxonidine: A Review of its Use in Essential Hypertension. Fenton, Caroline; Keating, Gillian M.; Lyseng-Williamson, Katherine A. // Drugs;2006, Vol. 66 Issue 4, p477 

    Moxonidine (Physiotens, Moxon, Cynt) is an orally administered imidazoline compound with selective agonist activity at imidazoline I1 receptors and only minor activity at α2-adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral...

  • Clinical outcomes of patients with diabetes mellitus receiving medication management by pharmacists in an urban private physician practice. Nkansah, Nancy T.; Brewer, Jeffrey M.; Connors, Robert; Shermock, Kenneth M. // American Journal of Health-System Pharmacy;1/15/2008, Vol. 65 Issue 2, p145 

    Purpose. The clinical outcomes of patients with diabetes mellitus in an urban environment receiving pharmacist medication management in collaboration with private-practice physicians were assessed. Methods. Patients older than 18 years with type 1 or 2 diabetes mellitus who were receiving oral...

  • Management in general practice of hypertensive patients poorly controlled with a fixed-dose renin�angiotensin system inhibitor and diuretic combination: results from a French national survey. Ragot, S.; Sosner, P.; Yau, C.; Brunel, P.; Herpin, D. // Journal of Human Hypertension;Jun2006, Vol. 20 Issue 6, p407 

    High rates of uncontrolled hypertensives have been reported in France as well as in other countries, partly owing to an inadequate management of hypertension by clinicians. The objectives of the study were (1) to describe the therapeutic decisions faced by general practitioners (GP) in...

  • Treatment and control of blood pressure in patients with diabetes mellitus. Hae Mi Choe; Townsend, Kevin A.; Blount, Gretchen; Chong Houa Lo; Sadowski, Linda; Standiford, Connie J. // American Journal of Health-System Pharmacy;1/1/2007, Vol. 64 Issue 1, p97 

    Purpose. A study was conducted to characterize the prevalence of hypertension in patients with diabetes mellitus and the percentage of patients with diabetes and hypertension who achieved a targeted blood pressure goal (<135/80 mm Hg). Methods. A retrospective, cross-sectional study was...

  • Bevantolol vs Propranolol: A Double-Blind Controlled Trial in Essential Hypertension. Maclean, Derek // Angiology;Jun1988, Vol. 39 Issue 6, p487 

    Bevantolol is a novel β1-selective beta-adrenoceptor antagonist. The Study Group evaluated its therapeutic utility (100–300 mg bid) compared with propranolol (80–240 mg bid) in 266 patients with mild to moderate essential hypertension (WHO Grades I and II, sitting diastolic...

  • New AHA guidelines help manage hypertension in the elderly. Garrett, Anna D. // Drug Topics;Apr2012, Vol. 156 Issue 4, p55 

    The article reports that the American Heart Association (AHA) has updated its guidelines for the treatment of hypertension in elderly patients. It states that when less than 150 millimetre of Mercury (mm Hg) systolic blood pressure (SBP) is obtained with 1 or 2 drugs, the treatment is...

  • Circadian Blood Pressure Pattern in Patients With Treated Hypertension and Left Ventricular Hypertrophy. Klein, Werner; Zweiker, Robert; Eber, Bemd; Dusleag, Johann; Brussee, Helmut; Rotman, Brigitte // Angiology;May1991, Vol. 42 Issue 5, p379 

    Left ventricular hypertrophy in hypertensives is an important determinant of prognosis. In the present study 45 patients with treated essential hypertension were divided into two groups: 23 patients had normal left ventricular dimension and 22 patients had echocardiographic signs of left...

  • Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type I diabetic patients. Spallone, V; Maiello, M R; Morganti, R; Mandica, S; Frajese, G // Journal of Human Hypertension;May2007, Vol. 21 Issue 5, p381 

    This study investigated whether nondipping (defined as a day–night change in blood pressure (BP) 0%) could be assumed as a diagnostic index for autonomic neuropathy, and assessed its accuracy in discriminating between type I diabetic patients with and without autonomic neuropathy....


Read the Article


Sign out of this library

Other Topics